Why Lineage, Inc. Stock Is Suddenly Climbing
Lineage, Inc. (LINE) stock is climbing due to several factors, including falling Treasury yields which benefit rate-sensitive REITs like Lineage, Inc. The company's focus on robotics and automation has received positive valuation commentary, and institutional investors have increased their positions. Additionally, a strong first-quarter earnings beat highlighted long-term efficiency gains, boosting investor confidence.
What Lineage (LINE)'s Q1 Move From Profit to Loss Means For Shareholders
Lineage, Inc. reported a Q1 2026 net loss of US$46 million and a loss per share of US$0.18, despite flat sales year-over-year. This shift from profit to loss highlights concerns about cost control and operational efficiency within the company's cold storage network. While the core investment narrative remains focused on occupancy and margin improvements, rising financing and trade pressures pose significant risks, underscoring the importance of management's expense management and technology initiatives.
What Lineage (LINE)'s Q1 Move From Profit to Loss Means For Shareholders
Lineage, Inc. reported a shift from profit to a net loss in Q1 2026, with sales remaining flat compared to the previous year. This change, resulting in a loss of US$46 million and US$0.18 basic and diluted loss per share, highlights concerns about cost pressures and operational efficiency. The article suggests that while the near-term focus will be on cost control and interest expense, the core investment narrative still hinges on improving occupancy and margins, alongside managing financing and trade pressures.
Earnings call transcript: Lineage Inc reports Q1 2026 earnings decline, stock dips
Lineage Inc. reported a challenging Q1 2026 with an EPS of -$0.18 and flat revenue of $1.3 billion, leading to a 0.55% stock price drop in pre-market trading. Despite a 3.3% rise in Adjusted EBITDA, the company faced significant declines in container volumes and lower AFFO per share. Executives noted signs of stabilization and maintained their full-year guidance, expressing confidence in operational efficiencies and strategic portfolio reviews.
Lineage, Inc. $LINE Stock Holdings Lifted by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. increased its stake in Lineage, Inc. ($LINE) by 11.2% in the fourth quarter, owning 926,149 shares worth $32.4 million. Several other institutional investors also adjusted their holdings. Analyst ratings for Lineage are mixed, with a consensus "Reduce" rating and an average price target of $43.28; however, the company reported strong Q1 earnings, beating estimates, and raised its quarterly dividend.
[10-Q] Lineage Cell Therapeutics, Inc. Quarterly Earnings Report
Lineage Cell Therapeutics (LCTX) reported Q1 2026 revenue of $1.7 million, an increase from $1.5 million in the prior year, primarily driven by collaboration income. Despite increased operating expenses totaling $9.3 million, the company's net loss attributable to Lineage was $4.8 million. As of March 31, 2026, Lineage held $53.4 million in cash, cash equivalents, and marketable securities, which management believes is sufficient to fund operations for at least the next twelve months.
Lineage Cell: Q1 Earnings Snapshot
Lineage Cell Therapeutics, Inc. (LCTX) reported a first-quarter loss of $4.8 million, or 3 cents per share. The biotechnology company's revenue for the period was $1.7 million, which fell short of analyst expectations of $3.2 million. This financial update was generated using data from Zacks Investment Research.
Earnings call transcript: Lineage Inc reports mixed Q1 2026 results amid market volatility
Lineage Inc (LINE) reported mixed Q1 2026 results with flat revenue of $1.3 billion and an EPS loss of $0.18, yet its stock saw a significant pre-market surge. The company emphasized its strategic initiatives, particularly the expansion of its LinOS technology platform and new automated facilities, despite challenges like market saturation and global supply chain disruptions. Executives expressed cautious optimism for stabilization and future growth, maintaining their full-year guidance but with increased conviction in reaching the midpoint.
Earnings call transcript: Lineage Inc reports mixed Q1 2026 results amid market volatility
Lineage Inc (LINE) reported mixed Q1 2026 results with flat revenue of $1.3 billion and an EPS loss of $0.18, yet its stock surged 9.51% pre-market due to investor confidence in strategic initiatives. The company maintained its 2026 guidance, expecting stabilization and benefits from its LinOS technology platform and new automated facilities despite industry headwinds like excess capacity and trade volatility. Executives expressed cautious optimism, highlighting strong international performance and ongoing cost management efforts.
Lineage Cell: Q1 Earnings Snapshot
Lineage Cell Therapeutics, Inc. (LCTX) reported a first-quarter loss of $4.8 million, translating to 3 cents per share. The biotechnology company generated $1.7 million in revenue, which fell short of analysts' expectations of $3.2 million. This earnings snapshot was generated by Automated Insights using data from Zacks Investment Research.
Why Lineage (LINE) Is Up 8.4% After Beating FFO Estimates And Reaffirming 2026 Guidance
Lineage (LINE) reported strong Q1 2026 results, exceeding FFO estimates despite a net loss and reaffirming its full-year 2026 guidance. The company's stock rose 8.4% as management highlighted ongoing plans to reduce administrative costs and conduct a portfolio review to enhance financial flexibility in a competitive cold storage market. While the dividend saw a modest increase, the focus remains on cost savings and efficiency to support future funds from operations and payouts.
Why Lineage (LINE) Is Up 8.4% After Beating FFO Estimates And Reaffirming 2026 Guidance
Lineage, Inc. saw an 8.4% stock price increase after reporting Q1 2026 results that exceeded FFO estimates despite industry challenges. The company reaffirmed its full-year 2026 guidance, initiated an over US$50 million administrative cost reduction plan by 2027, and is conducting a portfolio review to enhance financial flexibility in a saturated cold storage market. This focus on cost efficiency and strategic adjustments aims to support Lineage's financial performance amidst persistent oversupply and trade volatility.
Analysts Offer Insights on Real Estate Companies: Lineage, Inc. (LINE) and Frasers Logistics & Commercial Trust (OtherFRLOF)
Analysts from Piper Sandler and CGS International have provided insights on two real estate companies, Lineage, Inc. (LINE) and Frasers Logistics & Commercial Trust (FRLOF). Lineage received a reiterated Hold rating with a $35.00 price target, while Frasers Logistics & Commercial Trust was reiterated with a Buy rating and a price target of S$1.10. Both companies have varying analyst consensus ratings and implied upsides.
Analysts Offer Insights on Real Estate Companies: Lineage, Inc. (LINE), Macerich (MAC) and Realty Income (O)
Analysts have provided new ratings for three real estate companies: Lineage, Inc. (LINE), Macerich (MAC), and Realty Income (O). Lineage received a "Hold" rating from Scotiabank with an average price target implying an 8.6% upside. Macerich was maintained as a "Buy" by Truist Financial with an average target indicating a slight downside, while Realty Income also received a "Buy" rating from Stifel Nicolaus, suggesting a 7.0% upside.
Vanguard Group Inc. Sells 52,128 Shares of Lineage, Inc. $LINE
Vanguard Group Inc. reduced its stake in Lineage, Inc. by 0.6% in the fourth quarter, selling 52,128 shares and now owning 9,055,669 shares valued at approximately $316.95 million. This follows mixed Q1 results for Lineage, which saw EPS beat consensus but revenue slightly miss, alongside ongoing occupancy headwinds and a GAAP net loss despite management reiterating AFFO guidance and targeting cost savings. Insider buying by Chairman Kevin Marchetti and a dividend increase further characterize recent activity around the company.
US Cold Storage Market Is Going to Boom Rapidly | Lineage Logistics, Americold Logistics, U.S. Cold Storage, Inc.
The US cold storage market is projected to grow rapidly, from an estimated USD 52.28 billion in 2026 to USD 105.98 billion by 2033, exhibiting a compound annual growth rate of 12.5%. A new report from Coherent Market Insights details this growth, driven by increasing demand and continuous innovation, and provides in-depth analysis of market dynamics, segmentation, and competitive landscapes. The report covers key players, technological advancements, and offers strategic insights for industry leaders and investors.
Number of shareholders of Lineage, Inc. – NASDAQ:LINE
This article provides access to the number of shareholders for Lineage, Inc. (NASDAQ: LINE) through TradingView's financial data. It allows users to view historical values and percentage changes over different periods. The data is sourced from ICE Data Services and FactSet Research Systems Inc.
Lineage Cell Therapeutics, Inc. (LCTX) Presents at FFB Retinal Therapeutics Innovation Summit - Slideshow
Lineage Cell Therapeutics, Inc. (LCTX) presented at the FFB Retinal Therapeutics Innovation Summit, publishing a slide deck in conjunction with the event. The article highlights this presentation and was written by SA Transcripts, a team responsible for developing transcript-related projects for Seeking Alpha.
Why Lineage, Inc. Shares Are Sliding Now
Lineage, Inc. (LINE) shares are declining due to investor concerns over flat revenue, weaker volumes, and a dip in adjusted funds from operations (AFFO) per share, primarily attributed to expired hedges. Despite these concerns, management highlighted a Q1 EBITDA beat, positive pricing trends, and a strong development pipeline, along with a reaffirmed 2026 outlook, to reassure investors about future growth.
Lineage, Inc. Earnings Call Balances Progress And Risk
Lineage, Inc. reported better-than-expected adjusted EBITDA in Q1 2026 despite flat revenue and soft volumes, showcasing operational resilience. The company is making progress on pricing, technology, and cost savings, with a development pipeline poised to add significant EBITDA. However, challenges remain with a decline in AFFO per share, elevated leverage, and excess capacity in some U.S. markets, though management maintains confidence in its full-year guidance.
Lineage, Inc. Reports First-Quarter 2026 Financial Results
Lineage, Inc. (NASDAQ: LINE) announced its financial results for the first quarter of 2026, reporting total revenue of $1,297 million, a 0.4% increase, and adjusted EBITDA of $314 million, up 3.3%. Despite geopolitical disruptions and tariff uncertainty, the company delivered results ahead of expectations, with core business trends aligning with seasonal patterns, indicating industry stabilization. Lineage reiterated its full-year 2026 guidance, expecting adjusted EBITDA between $1.25 billion and $1.30 billion, and Adjusted FFO per share from $2.75 to $3.00.
Lineage, Inc. Reports First-Quarter 2026 Financial Results
Lineage, Inc. (NASDAQ: LINE) announced its first-quarter 2026 financial results, reporting a 0.4% increase in total revenue to $1,297 million, and a 3.3% rise in Adjusted EBITDA to $314 million, with an increased margin of 24.2%. Despite a GAAP net loss of $(51) million, the company maintained its full-year 2026 guidance for Adjusted EBITDA and Adjusted FFO per share, citing stabilizing industry trends and effective navigation of a dynamic operating environment.
Earnings call transcript: Lineage Inc reports Q1 2026 earnings decline, stock dips
Lineage Inc. reported a challenging Q1 2026 with an EPS of -$0.18, missing expectations, and flat revenue of $1.3 billion, causing its stock to drop. Despite a 3.3% increase in adjusted EBITDA, the company faced significant headwinds from a 17% decline in container volumes and expiring interest rate hedges. Lineage maintains its full-year 2026 guidance, expecting continued challenges but expressing increased confidence in achieving the midpoint due to signs of stabilization and strategic initiatives like its LinOS technology and cost rationalization efforts.
Lineage Releases Q1 2026 Financial Results
Lineage, Inc. (LINE) reported a Q1 2026 diluted loss of $0.18 per share, significantly wider than the expected loss of $0.06. Despite a net loss of $51.0 million, revenue increased by 0.4% year-over-year to $1.30 billion, driven by its Global Warehousing segment. The company provided FY 2026 guidance for FFO per share and Adjusted EBITDA, while Wall Street analysts remain mixed on the stock.
Lineage, Inc. (LINE) Q1 FFO Beat Estimates
The article reports that Lineage, Inc. (LINE) exceeded its Q1 FFO estimates. Further details about the financial performance or specific figures are not available in the provided content. The main body of the content is a privacy notice.
Lineage misses estimates as warehousing challenges persist
Lineage, Inc. (NASDAQ:LINE) reported Q1 2026 results that missed analyst expectations, with adjusted earnings per share of $0.78. The company's revenue was flat year-over-year at $1.30 billion, and its Global Warehousing segment experienced a decline in same warehouse net operating income and physical occupancy due to lower import/export volumes. Despite these challenges, Lineage maintained its full-year 2026 guidance and plans to remove $50 million of annualized costs by 2027.
Lineage, Inc. (NASDAQ: LINE) Q1 2026 earnings, AFFO and 2026 guidance
Lineage, Inc. reported its Q1 2026 financial results, with total revenue up 0.4% year-over-year to $1,297 million, and Adjusted EBITDA increasing 3.3% to $314 million. The company, however, posted a GAAP net loss of $51 million and a 9.3% decrease in Adjusted FFO per share to $0.78, largely due to higher depreciation and interest costs. Lineage maintained its full-year 2026 guidance for Adjusted EBITDA of $1.25–$1.30 billion and AFFO per share of $2.75–$3.00, and declared a quarterly dividend of $0.5325 per share.
Lineage, Inc. (NASDAQ:LINE) Receives Consensus Rating of "Reduce" from Analysts
Lineage, Inc. (NASDAQ:LINE) has received a consensus "Reduce" rating from twenty analysts, with an average 1-year target price of $43.06 against its current trading price of around $36.50. The company reported a significant earnings miss ($0.03 EPS vs. $0.73 expected) and has negative net margin and P/E, yet it increased its quarterly dividend to $0.5325, offering a yield of approximately 5.8%. Despite the mixed financial performance, insider ownership is high at 71.9%, with Chairman Kevin P. Marchetti recently purchasing 13,300 shares.
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) announced it will report its first quarter 2026 financial and operating results on Thursday, May 12, 2026, after the U.S. financial markets close. The clinical-stage biotechnology company developing allogeneic cell therapies will also host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss results and provide a business update. Interested parties can access the call via dialing (800) 715-9871 (Conference ID: 9229676) or through a live webcast on Lineage’s website.
Biotech Lineage will discuss quarterly results and a business update May 12
Lineage Cell Therapeutics (LCTX) will release its first-quarter 2026 financial and operating results on Thursday, May 12, 2026, after the U.S. financial markets close. The company's management will concurrently host a conference call and webcast to discuss these results and provide a business update. This session will be held at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on the same day.
Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital
This article states that Lineage Cell Therapeutics has been maintained at a "Buy" rating by D. Boral Capital. It implies that the analyst firm sees continued upside for the company's stock.
ETFs Investing in Lineage, Inc. Stocks
This article lists various ETFs that hold Lineage, Inc. (LINE) stocks, providing financial details for each fund. The ETFs cover different management styles and focus areas, such as real estate, small-cap, mid-cap, and large-cap, highlighting a diversified approach to investing in Lineage, Inc. through exchange-traded funds.
Return on assets % of Lineage, Inc. – BMV:LINE
This article displays the "Return on assets %" for Lineage, Inc. (BMV:LINE) on TradingView. It provides financial data specifically for this metric and highlights that the market is closed with no trades. The content primarily focuses on the financial overview of Lineage, Inc. within the Mexican Stock Exchange.
Analysts’ Opinions Are Mixed on These Real Estate Stocks: Lineage, Inc. (LINE), Brixmor Property (BRX) and Alexandria Equities (ARE)
This article provides an overview of recent analyst ratings for three real estate stocks: Lineage, Inc. (LINE), Brixmor Property (BRX), and Alexandria Equities (ARE). Goldman Sachs issued a Buy rating for Lineage, while Truist Financial maintained a Buy for Brixmor, and another Goldman Sachs analyst gave Alexandria Equities a Hold rating. The article includes average price targets and analyst consensus for each stock, highlighting the mixed opinions within the real estate sector.
[ARS] Lineage Cell Therapeutics, Inc. SEC Filing
This article announces an ARS SEC filing by Lineage Cell Therapeutics, Inc. (LCTX) on April 29, 2026. The filing has a low impact and neutral sentiment. The article also provides recent news and other SEC filings for LCTX, along with stock data.
Lineage to Report First-Quarter 2026 Financial Results on May 6, 2026
Lineage Inc. (LINE) is scheduled to report its first-quarter 2026 financial results on May 6, 2026. This announcement was delivered via Quantisnow, a real-time market data and news platform for retail investors. The article also provides recent analyst ratings and related insider and SEC filing insights for Lineage Inc.
Barclays downgrades Lineage (LINE)
Barclays has downgraded Lineage (LINE) stock. This indicates a revised, less optimistic outlook from the financial institution regarding the company's future performance.
Lineage (LINE) CAO RSU vesting leads to 205-share tax withholding
Lineage, Inc.'s Chief Accounting Officer, Abigail S. Fleming, had 205 shares of common stock withheld to cover tax obligations stemming from the vesting of Restricted Stock Units (RSUs). This transaction, valued at $35.55 per share, is a routine tax settlement and not an open-market sale. After the withholding, Fleming directly owns 18,277.14 shares of Lineage common stock.
Renaissance Capital LLC Sells 44,775 Shares of Lineage, Inc. $LINE
Renaissance Capital LLC significantly reduced its stake in Lineage, Inc. by selling 44,775 shares, cutting its holdings by 49.9%. Despite institutional selling and a significant earnings miss, Lineage increased its quarterly dividend, and its chairman purchased additional shares. The company has a "Reduce" consensus rating from analysts, with an average price target of $43.06.
Lineage (NASDAQ: LINE) sets 2026 virtual meeting, director slate and pay vote
Lineage, Inc. (NASDAQ: LINE) has announced its 2026 virtual annual meeting for shareholders on June 9, 2026, where investors will vote on the election of 10 directors, the ratification of PricewaterhouseCoopers LLP as the 2026 auditor, and an advisory vote on named executive officer pay. The proxy statement details the company's challenging first full year as a public entity in 2025, marked by cost-saving measures and operational improvements, leading to an improved outlook for 2026. Financial metrics, including outstanding shares, audit fees, and director compensation, are provided, along with information on changes in independent registered public accounting firms and executive officer compensation structures.
A Look At Lineage (LINE) Valuation After CIO And Transformation Leadership Transition News
Lineage's shares have been affected by news of a leadership transition, with a phased retirement plan for its CIO and CTO. Despite a recent share price return, its one-year total shareholder return has seen a significant decline. Analysts suggest Lineage is undervalued at $36.61, with a fair value of $40.44, based on potential profit margin convergence with the industry average, though this outlook is subject to risks like cold storage oversupply and high net debt.
A Look At Lineage (LINE) Valuation After CIO And Transformation Leadership Transition News
Lineage (LINE) shares are reacting to news of a phased retirement plan for its CIO and Chief Transformation Officer. The company, trading below analyst price targets and intrinsic value, is considered 9.5% undervalued based on a narrative that projects significant profit margin improvement. However, potential challenges like cold storage oversupply and high net debt could impact future performance.
Lineage Sets a New Standard for Protein Export Compliance
Lineage has addressed the complexities of exporting animal-protein products by developing a solution to ensure accuracy and prevent common errors like missing forms or documentation issues. The company aims to streamline the export process, minimizing shipment delays, rejections, or product returns for exporters. This initiative stems from Lineage's commitment to simplify compliance and ensure correctness with every shipment.
Kuehn Law Encourages Investors of Lineage, Inc. to Contact Law Firm
Kuehn Law is investigating Lineage, Inc. (NASDAQ: LINE) for potential breaches of fiduciary duties by its officers and directors. The firm alleges that Lineage misrepresented its financial and operational results prior to its IPO due to temporary market distortions. Investors who purchased LINE shares before August 1, 2024, are encouraged to contact Kuehn Law.
Lineage, Inc. Announces Chief Information Officer and Chief Transformation Officer Retirement and Transition Plan; Greg Lehmkuhl Comments
Lineage, Inc. announced the planned retirement of its Chief Information Officer and Chief Transformation Officer, Sudarsan Thattai, in April 2027. A phased transition plan is in place, with Chris Johnson stepping into day-to-day leadership of Lineage’s global IT and Technology organization. Greg Lehmkuhl, CEO, expressed gratitude for Thattai's 13 years of leadership in spearheading innovation and technology, particularly the development of LinOS.
Kuehn Law Encourages Investors of Lineage, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating Lineage, Inc. (NASDAQ: LINE) regarding potential breaches of fiduciary duties by its officers and directors. A federal securities lawsuit alleges that Lineage misrepresented its financial and operational results, which were temporarily inflated due to COVID-19 related market distortions and unsustainable price increases. The law firm is encouraging investors who bought LINE shares before August 1, 2024, to contact them.
Lineage, Inc. Announces Chief Information Officer and Chief Transformation Officer Retirement and Transition Plan; Greg Lehmkuhl Comments
Lineage, Inc. announced the planned retirement of its Chief Information Officer and Chief Transformation Officer, Sudarsan Thattai, who will transition out by April 2027. Chris Johnson will take over day-to-day leadership of the global IT and Technology organization. President and CEO Greg Lehmkuhl thanked Thattai for his 13 years of leadership and contributions, including developing LinOS.
Lineage, Inc. announces CIO and CTO retirement and transition plan
Lineage, Inc. has announced the planned retirement of its Chief Information Officer and Chief Transformation Officer, Sudarsan Thattai. Thattai will remain with the company until April 2027, focusing on high-impact IT priorities while Chris Johnson takes over day-to-day leadership of the global IT and Technology organization. This transition ensures a smooth handover and continued momentum on critical initiatives for the world's largest global temperature-controlled warehouse REIT.
Baillie Gifford & Co. Sells 167,958 Shares of Lineage, Inc. $LINE
Baillie Gifford & Co. has reduced its stake in Lineage, Inc. by 5.7%, selling 167,958 shares and now holding 2,786,283 shares valued at approximately $97.52 million. This comes as Lineage reported missed quarterly EPS and slightly below-forecast revenue, alongside a negative net margin and return on equity. Despite this, the company increased its quarterly dividend, and an insider purchased a significant number of shares.
Lineage Announces Formation of Scientific Advisory Board
Lineage Cell Therapeutics has announced the formation of a Scientific Advisory Board (SAB) to guide the development of its cell therapy pipeline. Dr. Joachim Fruebis, a distinguished executive with extensive experience in various therapeutic areas and cell therapy strategies, is the founding member. Additionally, Dr. Priyantha Herath, a Board-certified neurologist, has been appointed as Senior Vice President and Head of Clinical Operations, bringing broad clinical and regulatory development expertise to the company.
